{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nznmdp\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nznmdp\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;13\\\/16\\\/18\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;13\\\/16\\\/18\u0022}],\u0022ac\u0022:{\u0022spmdc;13\\\/16\\\/18\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;13\\\/16\\\/18\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/cdn\/css\/http\/css_Xg7z6oCTVgud_Q0huYz9x9iiD5H_2YPSJ5z2ZViSWdY.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n            \u003Cp id=\u0022p-1\u0022\u003EPersons with type 2 diabetes mellitus, especially the obese, tend to have more visceral fat than persons with type 1 [Gallager D et al. \u003Cem\u003EAm J Clin Nutr\u003C\/em\u003E 2009]. The hallmarks of diabetes are obesity and weight gain, mainly involving abdominal fat, and approaches to addressing these are discussed in this article. Other topics include the targeting low-density lipoprotein cholesterol (LDL-C) and waist circumference and the risk of cardiovascular disease.\u003C\/p\u003E\n         \u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003EExclusive Article - For home page\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ECardiometabolic Disorder\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EDiabetes Mellitus\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EObesity\u003C\/li\u003E\u003C\/ul\u003E\u003Cul class=\u0022kwd-group clinical-trial\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003EExclusive Article - For home page\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EEndocrinology\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EDiabetes \u0026amp; Metabolic Syndrome\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EDiabetes Mellitus\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EObesity\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ECardiometabolic Disorder\u003C\/li\u003E\u003C\/ul\u003E\u003Cp id=\u0022p-2\u0022\u003EThe hallmarks of diabetes are obesity and weight gain, mainly involving abdominal fat, and approaches to addressing these were discussed by Luc Van Gaal, MD, PhD, Antwerp University Hospital, Antwerp, Belgium. Persons with type 2 diabetes mellitus (T2DM), especially the obese, tend to have more visceral fat than persons with type 1 [Gallagher D et al. \u003Cem\u003EAm J Clin Nutr\u003C\/em\u003E 2009]. Conventional treatments of diabetes typically produce weight gain over time involving subcutaneous and visceral fat [UK Prospective Diabetes Study (UKPDS) Group. \u003Cem\u003ELancet\u003C\/em\u003E 1998; Kahn SE et al. \u003Cem\u003EN Engl J Med\u003C\/em\u003E 2006].\u003C\/p\u003E\u003Cp id=\u0022p-3\u0022\u003ETherapeutic weight control studies in patients with T2DM have assessed sulfonylurea, thiazolidinediones, insulin, metformin, dipeptidyl peptidase-4 inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Weight loss has been documented only for metformin (50% of cases) and GLP-1 receptor agonists [Drucker DJ. \u003Cem\u003EJ Clin Invest\u003C\/em\u003E 2007].\u003C\/p\u003E\u003Cp id=\u0022p-4\u0022\u003EDiet and aerobic exercise are beneficial in reducing visceral fat [Despr\u00e9s JP et al. \u003Cem\u003EAm J Physiol\u003C\/em\u003E 1991; Ross R et al. \u003Cem\u003EAnn Intern Med\u003C\/em\u003E 2000; Christiansen T et al. \u003Cem\u003EEur J Endocrinol\u003C\/em\u003E 2009]. Resistance exercise also reduces visceral fat and intrahepatic lipids [Lee S et al. \u003Cem\u003EDiabetes\u003C\/em\u003E 2012]. Aerobic and resistance exercise also reduces body weight and waist circumference in older individuals [Davidson LE et al. \u003Cem\u003EArch Intern Med\u003C\/em\u003E 2009]. Even without weight loss, exercise increases skeletal muscle mass, cardiorespiratory fitness, and insulin sensitivity [Ross R, Bradshaw AJ. \u003Cem\u003ENat Rev Endocrinol\u003C\/em\u003E 2009].\u003C\/p\u003E\u003Cp id=\u0022p-5\u0022\u003EOral drug therapy for weight and abdominal fat control in diabetes includes topiramate plus phentermine, and lipase inhibition (orlistat). Despite the weight lowering effects of sibutramine [Van Gaal LF et al. \u003Cem\u003EInt J Obes Relat Metab Disord\u003C\/em\u003E 1998], concerns about the increased risk of adverse cardiovascular (CV) events [James WP et al. \u003Cem\u003EN Engl J Med\u003C\/em\u003E 2010] have prevented approval in some countries.\u003C\/p\u003E\u003Cp id=\u0022p-6\u0022\u003ESecond-generation peripheral CB1 antagonists, 11\u03b2 hydroxysteroid dehydrogenase inhibitor, growth hormone in lipodystrophy, GLP-1 analogues (liraglutide, exenatide), SGLT-2 inhibitors (dapagliflozin), and leptin plus pramlintide are novel medications being studied to reduce intra-abdominal fat.\u003C\/p\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003ETARGETING LDL-C\u003C\/h2\u003E\n         \u003Cp id=\u0022p-7\u0022\u003EKwang Kon Koh, MD, PhD, Gachon University Gil Medical Center, Incheon, South Korea, discussed targeting low-density lipoprotein cholesterol (LDL-C) in patients with abdominal obesity.\u003C\/p\u003E\n         \u003Cp id=\u0022p-8\u0022\u003EPatients with hypertension and diabetes are at increased risk of CV events. Long-term survival is also significantly decreased compared to patients without diabetes [Verdecchia P et al. \u003Cem\u003EHypertension\u003C\/em\u003E 2004]. Thus preventing the development of diabetes is an important treatment goal.\u003C\/p\u003E\n         \u003Cp id=\u0022p-9\u0022\u003EVisceral fat is a hallmark of obesity and may drive inflammation and insulin resistance. In turn, this increases the risk of hypertension, T2DM, and dyslipidemia. These important risk factors increase the risk of developing atherosclerosis and cardiovascular disease (CVD) [Lim S et al. \u003Cem\u003ECirc J\u003C\/em\u003E 2011; Koh KK et al. \u003Cem\u003EInt J Cardiol\u003C\/em\u003E 2012].\u003C\/p\u003E\n         \u003Cp id=\u0022p-10\u0022\u003EAdipocytes produce bioactive molecules that participate in diverse metabolic processes [Lau DC et al. \u003Cem\u003EAm J Physiol Heart Circ Physiol\u003C\/em\u003E 2005; Wellen KE, Hotamisligil GS. \u003Cem\u003EJ Clin Invest\u003C\/em\u003E 2005] (\u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E). With increasing visceral adipose mass, adiponectin secretion decreases and the secretion of adipokines that reduce insulin sensitivity and contribute to endothelial dysfunction is increased. Thus, obesity and T2DM heighten CV risk.\u003C\/p\u003E\n         \u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/13\/16\/18\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Adipose Tissue as an Endrocrine Organ\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-932259996\u0022 data-figure-caption=\u0022Adipose Tissue as an Endrocrine Organ\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure 1.\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/13\/16\/18\/F1.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/13\/16\/18\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/13\/16\/18\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/13622\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption attrib\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1.\u003C\/span\u003E \n               \u003Cp id=\u0022p-11\u0022 class=\u0022first-child\u0022\u003EAdipose Tissue as an Endrocrine Organ\u003C\/p\u003E\n            \u003Cq class=\u0022attrib\u0022 id=\u0022attrib-1\u0022\u003ECRP=C-reactive protein; IL-6=interleukin-6; MCP-1=monocyte chemoattractant protein-1; PAI-1=plasminogen activator inhibitor-1; TNF-\u03b1=tumor necrosis factor-alpha\u003C\/q\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\n         \u003Cp id=\u0022p-12\u0022\u003ESimvastatin lowers adiponectin and reduces insulin sensitivity in patients with hypercholesterolemia [Koh KK et al. \u003Cem\u003EDiabetes Care\u003C\/em\u003E 2008], while atorvastatin and rosuvastatin increase glucose and insulin sensitivity in such patients [Koh KK et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E 2010; Koh KK et al. \u003Cem\u003EInt J Cardiol\u003C\/em\u003E 2013]. Atorvastatin and rosuvastatin mildly increase the risk of diabetes [Sattar N et al. \u003Cem\u003ELancet\u003C\/em\u003E 2010; Goldstein MR, Mascitelli L. \u003Cem\u003ECurr Diab Rep\u003C\/em\u003E 2013].\u003C\/p\u003E\n         \u003Cp id=\u0022p-13\u0022\u003EHowever, insulin resistance and endothelial dysfunction are both subject to multiple influences. Interactions between insulin resistance and endothelial function may mediate the pathophysiology of conditions such as diabetes, obesity, dyslipidemia, coronary artery disease, hypertension, and atherosclerosis [Mora S et al. \u003Cem\u003ECirculation\u003C\/em\u003E 2012]. Combined statin-based therapy has shown promise in improving oxidative stress [Koh KK et al. \u003Cem\u003ECirculation\u003C\/em\u003E 2004], altering levels of triglycerides and high-density lipoprotein cholesterol, and increasing insulin sensitivity [Koh KK et al. \u003Cem\u003EHypertension\u003C\/em\u003E 2005; Koh KK et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E 2005].\u003C\/p\u003E\n         \u003Cp id=\u0022p-14\u0022\u003EThus, despite the concerns about an increase risk of diabetes with use of potent statins, they have a central role in the primary and secondary prevention of coronary heart disease (CHD), in concert with modifiable lifestyle changes, stated Prof. Koh (\u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E).\u003C\/p\u003E\n         \u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022\/\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/13624\/expansion?postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 html=\u00221\u0022 fragment=\u0022#\u0022 external=\u00221\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/13624\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/13624\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1.\u003C\/span\u003E \n               \u003Cp id=\u0022p-15\u0022 class=\u0022first-child\u0022\u003EPractical Recommendations for Statin Choice\u003C\/p\u003E\n            \u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-2\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003EHYPERTRIGLYCERIDEMIC WAIST AND CARDIOMETABOLIC RISK\u003C\/h2\u003E\n         \u003Cp id=\u0022p-18\u0022\u003EBenoit Arsenault, PhD, Universit\u00e9 Laval, Qu\u00e9bec City, Qu\u00e9bec, Canada, discussed waist circumference and the risk of CVD.\u003C\/p\u003E\n         \u003Cp id=\u0022p-19\u0022\u003EMyocardial infarction risk increases with increasing body mass index (BMI) and waist circumference [Yusuf S et al. \u003Cem\u003ELancet\u003C\/em\u003E 2005]. Visceral, but not subcutaneous adiposity, is associated with adverse CV events [Britton KA et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E 2013].\u003C\/p\u003E\n         \u003Cp id=\u0022p-20\u0022\u003EStudies have indicated the importance of the hypertriglyceridemic (HyperTG) waist phenotype \u2014 the combination of increased waist circumference and elevated triglycerides \u2014 for prediction of cardiometabolic risk and associated CVD risk. The relationship between visceral fat and increased coronary artery calcium score in HyperTG waist patients with T2DM has been described [Sam S et al. \u003Cem\u003EDiabetes Care\u003C\/em\u003E 2009], as has the increased risk of coronary heart disease [Arsenault BJ et al. \u003Cem\u003ECan Med Assoc J\u003C\/em\u003E 2010]. In the latter study, the HyperTG waist phenotype was associated with the most precipitous decline in probability of event-free survival.\u003C\/p\u003E\n         \u003Cp id=\u0022p-21\u0022\u003EThe collective findings have led to a number of conclusions and recommendations (\u003Ca id=\u0022xref-table-wrap-2-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003ETable 2\u003C\/a\u003E).\u003C\/p\u003E\n         \u003Cdiv id=\u0022T2\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022\/\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/13626\/expansion?postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 html=\u00221\u0022 fragment=\u0022#\u0022 external=\u00221\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/13626\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/13626\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 2.\u003C\/span\u003E \n               \u003Cp id=\u0022p-22\u0022 class=\u0022first-child\u0022\u003EImportant Aspects of the HyperTG Waist\u003C\/p\u003E\n            \u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-3\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003EGLOBAL CARDIOMETABOLIC APPROACH ORGANIZATION AS A MODEL\u003C\/h2\u003E\n         \u003Cp id=\u0022p-23\u0022\u003EDenis Richard, PhD, Universit\u00e9 Laval, Qu\u00e9bec City, Qu\u00e9bec, Canada, reviewed the Canadian network for research in cardiometabolic health, diabetes, and obesity (CMDO).\u003C\/p\u003E\n         \u003Cp id=\u0022p-24\u0022\u003EThe prevalence of obesity in Canada has increased from almost 15% in 1979 to nearly 25% in 2008. Canada ranks among the top nations globally in terms of national prevalence of diabetes, which, for Canadians aged 35 to 39 years and 40 to 44 years has increased from 1.5% and 2% respectively in 1998, to 2.5% and 4% respectively in 2008. Thirty three percent of Canadians die of diabetes-related causes annually.\u003C\/p\u003E\n         \u003Cp id=\u0022p-25\u0022\u003EThe CMDO network comprises research silos of cardiometabolic health, diabetes, and obesity. The CMDO network emphasizes basic and preclinical research, nutrition, physical activity, human physiopathology, lifestyle habits, population health, health care delivery and policy and knowledge dissemination\/exchange.\u003C\/p\u003E\n         \u003Cp id=\u0022p-26\u0022\u003EAs CMDO strives to move away from a silo-based approach, long-term collaborative research will be needed to study the association of cardiometabolic health, diabetes, and obesity with respiratory diseases and cancer [Boulet LP. \u003Cem\u003EClin Exp Allergy\u003C\/em\u003E 2013] [Gilbert CA, Slingerland JM. \u003Cem\u003EAnn Rev Med\u003C\/em\u003E 2013].\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2013 MD Conference Express\u00ae\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/13\/16\/18.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_figures.js?nznmdp\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nznmdp\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_tables.js?nznmdp\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}